Full text is available at the source.
Abstract
Obstructive Sleep Apnea (OSA) is associated with repeated episodes of airway obstruction during sleep, leading to negative impacts on health.
- OSA is marked by intermittent hypoxia and fragmented sleep.
- Obesity is a significant modifiable risk factor for OSA, contributing to airway collapse.
- Continuous positive airway pressure (CPAP) therapy is the standard treatment, but patient adherence is often an issue.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to reduce body weight and improve metabolic health.
- Emerging evidence suggests GLP-1 RAs may help manage OSA by addressing obesity.
Simplified